28445938|t|Pirfenidone normalizes the tumor microenvironment to improve chemotherapy
28445938|a|Normalization of the tumor microenvironment by selectively targeting components of the tumor extracellular matrix has been recently proposed to have the potential to decompress tumor blood vessels, increase vessel perfusion and thus, improve drug delivery and the efficacy of cancer therapy. Therefore, we now need to identify safe and well tolerated pharmaceutical agents that are able to remodel the microenvironment of solid tumors and enhance chemotherapy. In this study, we repurposed Pirfenidone, a clinically approved anti-fibrotic drug for the treatment of idiopathic pulmonary fibrosis, to investigate its possible role on tumor microenvironment normalization. Using two orthotopic mammary tumor models we demonstrate that Pirfenidone reduces collagen and hyaluronan levels and, as a result, significantly increases blood vessel functionality and perfusion and improves the anti-tumor efficacy of doxorubicin. Reduction of extracellular matrix components were mediated via TGFβ signaling pathway inhibition due to downregulation of TGFβ1, COL1A1, COL3A1, HAS2, HAS3 expression levels. Our findings provide evidence that repurposing Pirfenidone could be used as a promising strategy to enhance drug delivery to solid tumors by normalizing the tumor microenvironment.
28445938	0	11	Pirfenidone	T109,T121	C0298067
28445938	12	22	normalizes	T169	C0599112
28445938	27	49	tumor microenvironment	T070	C2936626
28445938	61	73	chemotherapy	T061	C3665472
28445938	74	87	Normalization	T061	C0556530
28445938	95	117	tumor microenvironment	T070	C2936626
28445938	133	142	targeting	T169	C1521840
28445938	143	153	components	T026	C0932050
28445938	161	166	tumor	T191	C0027651
28445938	167	187	extracellular matrix	T024	C0015350
28445938	227	236	potential	T080	C3245505
28445938	240	250	decompress	T169	C1965697
28445938	251	256	tumor	T191	C0027651
28445938	257	270	blood vessels	T023	C0005847
28445938	272	280	increase	T169	C0442805
28445938	281	287	vessel	T023	C0005847
28445938	288	297	perfusion	T042	C0599705
28445938	316	329	drug delivery	T061	C0087111
28445938	338	346	efficacy	T080	C0598333
28445938	350	364	cancer therapy	T061	C0920425
28445938	392	400	identify	T080	C0205396
28445938	415	424	tolerated	T033	C0243095
28445938	425	446	pharmaceutical agents	T121	C1254351
28445938	476	492	microenvironment	T070	C2936626
28445938	496	508	solid tumors	T191	C0280100
28445938	513	520	enhance	T052	C2349975
28445938	521	533	chemotherapy	T061	C3665472
28445938	543	548	study	T062	C2603343
28445938	564	575	Pirfenidone	T109,T121	C0298067
28445938	579	589	clinically	T080	C0205210
28445938	590	598	approved	T080	C0205540
28445938	599	617	anti-fibrotic drug	T121	C4031950
28445938	626	635	treatment	T061	C0087111
28445938	639	668	idiopathic pulmonary fibrosis	T047	C1800706
28445938	673	684	investigate	T169	C1292732
28445938	706	728	tumor microenvironment	T070	C2936626
28445938	729	742	normalization	T061	C0556530
28445938	754	764	orthotopic	T082	C0574893
28445938	765	772	mammary	T023	C0006141
28445938	773	785	tumor models	T170	C1710493
28445938	806	817	Pirfenidone	T109,T121	C0298067
28445938	818	825	reduces	T081	C0547047
28445938	826	834	collagen	T116	C0009325
28445938	839	849	hyaluronan	T109,T121,T123	C0813622
28445938	850	856	levels	T080	C0441889
28445938	867	873	result	T169	C1274040
28445938	875	888	significantly	T078	C0750502
28445938	889	898	increases	T169	C0442805
28445938	899	911	blood vessel	T023	C0005847
28445938	912	925	functionality	T169	C0542341
28445938	930	939	perfusion	T042	C0599705
28445938	957	976	anti-tumor efficacy	T080	C0598333
28445938	980	991	doxorubicin	T109,T195	C0013089
28445938	993	1002	Reduction	T080	C0392756
28445938	1006	1037	extracellular matrix components	T026	C0932050
28445938	1056	1078	TGFβ signaling pathway	T169	C2984328
28445938	1079	1089	inhibition	T052	C3463820
28445938	1097	1111	downregulation	T044	C0013081
28445938	1115	1120	TGFβ1	T028	C1366557
28445938	1122	1128	COL1A1	T028	C1332772
28445938	1130	1136	COL3A1	T028	C1413581
28445938	1138	1142	HAS2	T028	C1415475
28445938	1144	1148	HAS3	T028	C1415476
28445938	1149	1159	expression	T045	C0017262
28445938	1160	1166	levels	T080	C0441889
28445938	1172	1180	findings	T033	C0243095
28445938	1189	1197	evidence	T078	C3887511
28445938	1215	1226	Pirfenidone	T109,T121	C0298067
28445938	1256	1264	strategy	T062	C0035171
28445938	1268	1275	enhance	T052	C2349975
28445938	1276	1289	drug delivery	T061	C0087111
28445938	1293	1305	solid tumors	T191	C0280100
28445938	1309	1320	normalizing	T061	C0556530
28445938	1325	1347	tumor microenvironment	T070	C2936626